In the first week of August, results from a clinical trial conducted with Duke University colleagues at Duke’s Comprehensive Cancer Center were published online in the Journal of Clinical Investigation. The results are the first reported for AlphaVax’s proprietary alphavirus-based platform in cancer immunotherapy, and they confirm the exciting potential of this platform for addressing cancer. AlphaVax manufactured the vaccine used in this clinical trial at its manufacturing facility in Lenoir, North Carolina.

Under existing grant support from the NIH, AlphaVax has completed the manufacture, testing and release assays of GMP-compliant clinical trial material for a filovirus vaccine candidate at its pilot facility in Lenoir, North Carolina. Further development to advance a multivalent vaccine against Marburg and Ebola viruses into clinical testing is currently under review. Such development will include consideration of the Request for Information (RFI) released by the U.S. Army on January 15, 2010, under which the Department of Defense is seeking companies with the experience and capability to advance Filovirus Vaccine(s) to Food and Drug Administration (FDA) Approval.

AlphaVax announced today the presentation of promising results from a collaboration with researchers at the Memorial Sloan-Kettering Cancer Center (MSKCC). Pre-clinical studies conducted in the laboratory of Dr. Jedd Wolchok demonstrate the ability of AlphaVax’s virus-like replicon vector particles (VRP) encoding melanoma-specific tumor antigens to reduce tumor burden in a state-of-the-art murine melanoma model.